Patent intelligence · US
US 12383733
Iontophoresis-based patch type medicine absorption device
Iontophoresis-based patch type medicine absorption device
Patent details — US 12383733
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 12, 2025
- Expiration
- Aug 7, 2045
- Applicant
- ROOTONIX Co., Ltd.
- Claims
- 20
- CPC classes
- A61K, A61K9/0009, A61K9/7023
Quick answer
US 12383733 (Iontophoresis-based patch type medicine absorption device) is held by ROOTONIX Co., Ltd.. Status: granted. Granted Aug 12, 2025. Expires Aug 7, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ROOTONIX Co., Ltd.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K9/0009, A61K9/7023
More from ROOTONIX Co., Ltd.
Related pharmaceutical patents in our USPTO index.
-
US 12365879
Synthetic chimeric poxviruses
granted -
US 12304901
Selective ligands for tau aggregates
granted -
US 12156897
Magnesium-containing oxytocin formulations and methods of use
granted -
US 12156864
Analogs of cyclobenzaprine and amitryptilene
granted -
US 12097183
Pharmaceutical composition for treating migraine
granted -
US 12090139
Formulations comprising triptan compounds
granted -
US 11998516
Methods and compositions for treating depression using cyclobenzaprine
granted
Frequently asked questions
What is US patent 12383733?
US 12383733 (Iontophoresis-based patch type medicine absorption device) is held by ROOTONIX Co., Ltd.. Status: granted. Granted Aug 12, 2025. Expires Aug 7, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12383733?
ROOTONIX Co., Ltd. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 86 pharmaceutical patents for this assignee.
When does US 12383733 expire?
Our index shows an expiration date of Aug 7, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.